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EXECUTIVE SUMMARY 
 
Background 
 
There is evidence that certain medications can impair driving performance. A key traffic safety 
countermeasure used in Australia to alert consumers to the risk is the display of warnings on 
medications that have the potential to impair driving. There is recent evidence, supported in some 
areas in this study, that Australian consumers have low levels of knowledge and awareness of 
possible impairing effects. This raises the question of the effectiveness of the warnings, and whether 
there are ways in which they can be improved to enhance their impact on consumer awareness and 
behaviour.  
 
While there is a large body of research investigating warning effectiveness, very little research has 
specifically investigated medication warnings about driving impairment. The Australian warning 
approach requires consumers to self-assess any impairment, while an alternative approach in use in 
France advises consumers to seek advice from a health professional about driving. The French 
warnings also differ on visual characteristics and have a system of graded risk communication. 
Another difference is that the highest risk Australian warning also raises the need monitor associated 
alcohol use. 
 
Research objectives and design 
 
The project aims to examine the effectiveness of medication warnings about driving from the 
perspective of consumers and health professionals. The project compares differing content 
messages, different readability and visual presentations, and measures knowledge of, attitudes 
towards, and responses to the warnings currently used in Australia. It provides baseline Australian 
data in this increasingly important area and for clarification it compares Australian labeling with the 
new French medication labeling system. The study provides evidence to inform the development of 
future effective medication labeling in order to raise community awareness of the risks of impaired 
driving as a consequence of using medications, particularly in combination with alcohol. 
 
Baseline (n = 358) and follow-up (n = 53) surveys of public hospital outpatients were conducted in 
Queensland, Australia. Information was obtained from a sample of hospital pharmacy outpatients who 
were selected for study because they were considered to be high-level medication users in an optimal 
pharmacy best practice situation. Questions were asked about their driving; medication use; 
perceptions and ratings of the characteristics of the Australian and French warnings; knowledge; 
attitudes, measured by risk perceptions and driving  behaviour after taking a medication that 
displayed a warning label. A complementary study of 98 community based French health 
professionals is also reported. 
 
In the initial design of this NRMA – ACT Trust study a parallel comparison of warning label 
expectations of an Australian Health Professional sample was also proposed and approved. 
Recruitment for this phase has proved more difficult than anticipated and at the time of writing is 
incomplete.  
 
Results 
 
Study results suggest that the Australian warning approach of using a combination of visual 
characteristics is important, but that the use of a pictogram could enhance effects. Significantly higher 
levels of risk perception were found among the Australian sample for the French highest severity label 
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compared with the analogous mandatory Australian warning, with a similar trend evident in the French 
study results. Knowledge of warning labels was relatively high with the exception of underestimating 
the risk incurred from exceeding the prescribed dose, and at the time of commencing treatment.  
 
Participants reported generally accurate knowledge concerning the effects of medicines and other 
substances on driving. However, three of the assessment items were associated with incorrect 
responses. These concerned underestimating the risk incurred from discontinuing medication; 
exceeding the prescribed dose, and at the time of commencing treatment.  
 
It is of concern that at the follow up survey of  this well advised sample of people who were on high 
risk medications only just over half (51%) recalled seeing a warning label on their medications. Whilst 
three quarters (78%) of these respondents reported following the warning label advice this still leaves 
a large proportion of people who do not take the warning into account in making their decisions about 
driving. 
 
 Responses also showed variation concerning alcohol intake and there was evidence that patients 
would consider modifying the dose of medication or driving habits so that it was possible to continue 
driving.  
 
The French Health Professionals noted the Australian warning and expressed some concerns about 
the absence of reference to the possible increase of impairment due to alcohol use in the French 
warning system. 
 
Conclusions and recommendations 
 
The results are potentially important for the Australian approach to medication warnings about driving 
impairment. The research contributes both practical and theoretical findings that can be used to 
enhance the effectiveness of warnings and developing countermeasures in this area. Suggestions for 
future research relate to continued investigation of the effects of medication and other substances on 
driving skills, warning label design, and validation of consumer self-assessment of impairment. This 
project has involved persons with the highest level of likelihood of knowledge and awareness of 
medication warning labelling. Even in this context it would appear that a review of the Australian 
messaging system would be useful particularly in the context of increasing evidence relating to 
associated driving risks. The inclusion of the warning regarding potential increased risk associated 
with alcohol use was well supported. Reviewing text size, readability and simplicity of messages 
including the addition of pictograms as well as clarifying the importance of potential risk in a general 
community context is recommended for consideration and further research. 
  
  Page | 3 
LIST OF TABLES 
 
Table 1  Australian ancillary labels relating to driving 
Table 2  French medication warnings about driving 
Table 3 Demographic characteristics of Brisbane hospital outpatients who take medication on 
a daily basis 
Table 4  Alcohol and illicit drug use of Brisbane hospital outpatients who take medication on a 
daily basis 
Table 5  Frequency of 78 MIMS medication classes taken in last 7 days 
Table 6  Selected medication class – daily and occasional use in the last 12 months 
Table 7  Number of selected classes of prescription medication taken daily in last 12 months 
Table 8  Frequency of Labels 1, 1a and 12 on medications used in the 7 days prior to survey 
Table 9 Brisbane hospital outpatients’ ratings of impact of warning label visual characteristics 
Table 10 Brisbane hospital outpatients’ ratings of easiest warning to read 
Table 11 Brisbane hospital outpatients’ frequency of recall of warning label among participants 
who had taken at least one medication in last seven days 
Table 12 Brisbane hospital outpatients’ recall of warning label according to number of classes 
of medications taken 
Table 13  Brisbane hospital outpatients’ frequency of medication warning label recall according 
to warning label type, for medications used in last seven days 
Table 14  Brisbane hospital outpatients’ perceptions of which warning conveys the strongest 
message of risk 
Table 15  Brisbane hospital outpatients’ knowledge about the effects of medications, alcohol, 
illicit drugs and driving 
Table 16  Brisbane hospital outpatients’ intentions 
Table 17 Follow-up of hospital outpatients’ behavioural responses to taking medication that 
displayed a warning label 
Table 18 Sample Doctor and Pharmacist questionnaire items 
 
 
  
  Page | 4 
1 INTRODUCTION 
1.1 BACKGROUND 
 
There is growing research evidence that certain medications can negatively impair driving 
performance. Although methodological complications make comparisons and estimates difficult, 
epidemiological and experimental studies provide evidence of impairing effects. A review by Walsh et 
al. (2004) highlights six different drug types that are implicated: benzodiazepines, opioids, 
amphetamines/stimulants, cannabis, antihistamines, and antidepressants. Other researchers have 
identified up to nine classes of medicines that can impair driving (Alvarez and del Rio, 2002). The use 
of medications in combination with alcohol and other at risk medications or other classes of 
medications has also been found to exacerbate negative effects, and evidence of dose and treatment 
effects have also been demonstrated (Barbone et al., 1998; Drummer et al., 2004; Mura et al., 2003; 
Neutel, 1995, 1998; Ray, 1996; Ray, Fought & Decker, 1992).  
 
Community knowledge 
 
A recent internet survey of Australian drivers was conducted to obtain data on the prevalence of drug 
driving, including pharmaceutical drugs (Mallick et al., 2007). The sample responses indicated 
substantial pharmaceutical drug use and driving, with 15% reporting driving within three hours of 
taking analgesics, 4% after taking benzodiazepines, and 2.3% after taking prescription stimulants 
(Mallick et al., 2007). When asked how likely they would be to drive under the influence of prescription 
medication in the next 12 months, 13.6% responded that they would be “very likely” to drive following 
the use of analgesics. Approximately 14% responded that they would be “very likely” to drive after 
taking prescription stimulants, and 10.2% responded also being “very likely” to drive following use of 
benzodiazepines (Mallick et al., 2007, p. 78). The sample also indicated very low levels of knowledge 
on this issue. Between one third and a half of the driver sample reported not knowing how much time 
after taking analgesics, benzodiazepines or prescription stimulants it is safe to drive (Mallick et al., 
2007). 
 
Australian labeling regulations 
 
A primary safety countermeasure used in Australia and internationally to alert consumers to the risk is 
the display of warnings on medications that have the potential to impair driving. Medication labelling is 
primarily the responsibility of the Therapeutic Goods Administration (TGA). Labelling (including 
labelling warning about driving impairment) is based upon the active ingredient of the medication. All 
drugs and poisons are scheduled according to active ingredients in the Standard for the Uniform 
Scheduling of Medicines and Poisons (SUSMP) (TGA, 2010). The SUSMP (TGA, 2010) is intended to 
provide consistent guidelines for scheduling, packaging and labelling of drugs and poisons throughout 
Australia, based on the recommendations of the Advisory Committee on Medicines Scheduling 
(ACMS) (recently known as the National Drugs and Poisons Schedule Committee [NDPSC]). Thus 
the scheduling controls the source of the substance (e.g., pharmacist only, prescription only, over-the-
counter, etc.) and the information given to the consumer about the product. The Required Advisory 
Statements for Medicine Labels (RASML) (TGA, 2008b) stipulates the particular statements that 
should appear on the label of medication if it contains certain active ingredients and meets certain 
conditions. A further linked document, the Labelling Order, Therapeutic Goods Order 69 – General 
Requirements for Labels for Medicines (TGA, 2009), mandates medicine labels to include any 
advisory statements specified in the RASML.  
 
In addition, pharmacists in Australia are required to comply with the Pharmaceutical Society Australia 
(PSA) Code of Professional Conduct (PSA, 1998) and Professional Practice Standards (PSA, 2010). 
The PSA Professional Practice Standards stipulate that pharmacists “use appropriate cautionary 
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advisory labels on dispensed medicines as recommended in the current edition of the Australian 
Pharmaceutical Formulary and Handbook” (Standard 5, Criterion 8, p. 30, 2010). It also specifies that 
counselling be offered to ensure consumers have adequate knowledge of their medications. The 
Australian Health Practitioner Regulation Agency (AHPRA), which became the registering body for 
pharmacists in Australia in 2010, also provides professional guidelines for the dispensing of 
medicines, which recommend that relevant legislation regarding labelling should be followed. 
According to national guidelines, the current medication warning system requires the display of 
ancillary Label 1 or 1a, on medications that may cause drowsiness, which are listed in Appendix K of 
the SUSMP (2010). An additional ancillary label, Label 12, is applied at pharmacists’ discretion. A 
potentially related Australian warning, black-box warning labels, which alert prescribers to important 
safety information related to a medication and appear with a bold black surrounding box, are excluded 
from the scope of this research. While a black-box warning has recently been imposed upon the 
medication Stilnox due to reported adverse effects such as sleep-driving, the warnings have been 
recommended for a small number of medicines only (TGA, 2008a). The black-box warnings are 
therefore used in exceptional cases and are considered to lie outside the scope of this study. 
 
The Australian approach to minimising the risk, as delivered through the content of the warning, relies 
upon consumers to self-assess any impairment, and make their own decision about whether they are 
safe to drive. A review of the literature revealed a deficiency in research related to the approach to 
medicine warnings about driving currently in use in Australia. The little information available suggests 
that there are areas in which improvements can be made. It has been found in Australia (and 
elsewhere) that medication information, including labelling, is often too complicated to be understood, 
difficult to read, or simply not read or only partially read (Ley, 1995; Webb et al., 2008). To address 
such difficulties, researchers have recommended that medication labelling be developed to improve 
comprehension, and that patients be included in review and development processes to ensure 
materials are appropriately designed (Davis et al., 2006; Wolf & Cooper Bailey, 2007).  
 
Most recently, in 2006, an extensive review of the ancillary labels was undertaken by the Cautionary 
Advisory Labels Working Group, and included consultation with policy makers, consumer groups and 
external stakeholders such as Vision Australia to ensure the needs of the elderly and vision-impaired 
are met (Australian Pharmacist, 2006). The review aimed to address consumer issues concerning 
label design and enhance their health outcomes by reducing variation and error in labelling and 
improving consistency of the use of the labels by Australian pharmacies and the safe use of 
medicines by patients (Australian Pharmacist, 2006). The review outcomes included the stipulation of 
specific label colours, black or dark blue sans serif font on a white background to increase contrast, 
coloured borders, increasing the size of Labels 1 and 1a to allow for larger font size, increasing label 
width by 1mm on all other labels, and simplification of label wording (Australian Pharmacist, 2006). 
Although it is reported that “various options” and “different label presentations” were reviewed and 
trialed (Australian Pharmacist, 2006, p. 598), further details on the background and design of the 
labels were not available (TGA, PSA, PGA (QLD), personal communication, May 2010). The current 
label specifications are the result of the review by experts in pharmacology, label design and 
readability. However, as demonstrated by Mallick et al.’s study, there is evidence that Australian 
drivers have low levels of knowledge and drive soon after taking potentially impairing medication. This 
calls into question the effectiveness of the warnings and their impact on behaviour of the intended 
audience.  
 
The Australian warning labels are presented in Table 1 following. 
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Table 1 
Australian ancillary warning labels relating to driving 
Label name Warning labels 
 
Label 1 
 
  
Label 1a 
 
  
Label 12 
 
 
 
 
In contrast to the Australian system, an alternative approach in use in France advises consumers to 
seek advice from a health professional about driving. The French warnings also differ on visual 
characteristics and have a system of graded risk communication. This is based on the categorisation 
of medication classes into four categories of risk for driving impairment. In this categorisation system, 
Level 1 is a low level of risk, and associated with a yellow pictogram, Level 2 is a medium level of risk 
and associated with an orange pictogram, and Level 3 (the highest level of risk) is associated with a 
red pictogram. Table 2 displays the French (English translation) warning labels.  
 
 
Table 2 
French medication warnings about driving 
 
Medication class Warning labels 
Class 0  
Drugs which according to current knowledge do not 
pose any identified pharmacodynamic effect likely 
to impair control capacities. 
No pictogram 
Class 1  
Drugs which do not call into question control but 
require that the patients are informed. 
 
Class 2  
Drugs which can call into question the aptitude for 
driving and require a medical opinion.   
Class 3  
Drugs which call into question the aptitude for 
driving during their use. 
 
Note. AFSSAPS, 2005. 
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1.2 PROJECT AIM AND OBJECTIVES 
 
This NRMA-ACT Trust funded project examines the effectiveness of the Australian and French 
medication warnings about driving from the perspective of medication consumers and health 
professionals. It compares the differing content messages, different readability and visual 
presentations of the two approaches to warnings, and measures knowledge of, attitudes towards, and 
responses to the warnings currently used in Australia. The study aims to inform knowledge regarding 
the most effective medication labelling to raise community awareness of the risks of impaired driving 
as a consequence of using medications.  
 
The objectives of the study are to: 
 
1. Examine the effectiveness of medication information and warnings regarding potential for 
impaired driving performance in terms of user recall and comprehension 
2. Compare the Australian and the new French warning messages in terms of user recall and 
comprehension including the impact of alcohol 
3. Determine patient knowledge, attitudes and intentions regarding medication warnings and the 
barriers to following such warnings 
4. Examine the effect of patient variables such as age, ethnicity, attitudes to road safety on 
these factors  
5. Examine doctors and pharmacists attitudes and expectations about the effectiveness of 
medication warnings 
1.3 STRUCTURE OF THE REPORT 
 
The report outlines separately three components of the research. In Section 2, the study of hospital 
outpatients is reported (baseline survey). This includes an overview of the literature review findings 
concerning factors demonstrated to influence the effectiveness of warnings, the survey methodology, 
the results and discussion. In Section 3, the follow-up study of a sub-group of the baseline survey 
participants is reported. This section discusses the study methodology and findings. Section 4 reports 
the study of perceptions of French health professionals on the medication warnings. 
1.4 PROGRESS OF PROPOSED RESEARCH TASKS 
 
The present research program was undertaken as part of a PhD thesis. The thesis was submitted for 
external review on 25 August 2011. Selected results of the research have been presented at two 
international traffic safety conferences, including the International Traffic Medicine Association in The 
Hague (2009), and the International Council of Alcohol, Drugs and Traffic Safety in Oslo (2010). Peer-
reviewed journal publications from the research are currently in progress.  
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2 STUDY 1: HOSPITAL OUTPATIENTS 
2.1 METHODOLOGICAL ISSUES 
 
There is a large body of research investigating warning effectiveness, but very little research has 
specifically investigated medication warnings about driving impairment. A review of the literature 
relating to warning design highlights several key factors that have been demonstrated in research to 
influence warning noticeability and user compliance with warning advice. Evaluations of warning 
effectiveness have used varied measures of effectiveness. There is consensus among researchers in 
the field that behavioural compliance is a key indicator of effectiveness, and theoretical models of 
warning evaluation have been developed utilising this as the primary outcome measure (for example, 
the Communication-Human Information Processing model) (Wogalter, DeJoy, & Laughery, 1999).  
 
Factors such as resource costs and ethical considerations related to user safety have made studies 
using objective measures of behavioural compliance problematic (Smith-Jackson & Wogalter, 2006; 
Wogalter, Conzola, & Smith-Jackson, 2002). Research often uses behavioural intentions as a proxy 
measure of actual compliance (Wogalter et al., 2002). Some studies have utilised subjective ratings of 
other dimensions related to effectiveness, such as preferences, likelihood of reading or noticing the 
warnings, likelihood of compliance (Adams, Bochner, & Bilik, 1998; Kalsher, Wogalter, & Racicot, 
1996). Research has also used objective measures such as observation and warning recall (Barlow & 
Wogalter, 1993) though these have been noted as being potentially limited by measurement error, 
and they are resource-intensive (Smith-Jackson & Wogalter, 2006; Wogalter et al., 2002). Numerous 
studies have incorporated experimental manipulation (for example manipulating the presence or 
absence of warning characteristics), however these have also relied upon subjective ratings of 
outcome measures, making actual compliance in a real-world setting difficult to determine (Adams et 
al., 1998; Laughery, Young, Vaubel, & Brelsford, 1993).  
 
The present study uses self-report behaviour obtained from surveys. This method has been used 
extensively to determine the attention given to warnings and information obtained from them (for 
example, Davies, Haines, Norris, & Wilson, 1998; Kalsher et al., 1996). This method commonly 
assesses retrospective behaviour and is relatively inexpensive and easily conducted. In the warning 
efficacy context, it has been useful in determining the reasons for non-compliance, and beliefs and 
attitudes (Smith-Jackson & Wogalter, 2006).  
2.1.1 Factors influencing noticing and perceptions of warnings  
 
Laughery (2006) conducted a review of the relevant research and identified that the most important 
factors determining warning effectiveness were those that influence noticing, encoding, and 
compliance decisions. These factors relate to characteristics of the warning design and of the 
message recipients (Laughery, 2006). Warning design characteristics that have been demonstrated to 
be important for noticing and encoding include size, location, colour/contrast, signal words, and 
pictorials (Hellier, Edworthy, Derbyshire, & Costello, 2006; Laughery, 2006; Ley, 1995).  
 
2.1.1.1  Size of warning and text  
The size of the warning has been found to be important for noticing and recall, with bigger and bolder 
print demonstrating a positive effect on recall of the warning (Bernadini, Ambrogi, Fardella, Perioli, & 
Grandolini, 2001; Wogalter et al., 2002).  
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2.1.1.2 Signal words and colour  
There is evidence that coloured labels are perceived as more hazardous than black and white labels 
(Braun, Kline & Silver, 1995). Signal words attract attention and indicate the level of danger present 
with the three most common being “caution”, “warning”, and “danger” (Laughery, 2006). These are 
each associated with a colour that indicates the level of risk: caution with yellow, warning with orange, 
and danger with red (Laughery, 2006, p. 471). Research has demonstrated that the word “danger” 
attracts attention more than the words “caution” or “warning”, and implies the greatest hazard (Adams 
et al. 1998; Braun, Kline & Silver, 1995; Kline, Braun, Peterson, & Silver, 1993; Laughery et al., 1993; 
Wolgalter et al., 2002).  
 
2.1.1.3 Pictograms  
Pictograms (also referred to as pictorials) attract attention and communicate information, and may be 
in the form of photographs, drawings, and abstract symbols (Laughery, 2006; Wogalter, Silver, 
Leonard, & Zaikina, 2006). To be effective, they need to be both noticeable and understandable 
(Davies et al., 1998). The evidence for the effectiveness of pictograms in warning labels is mixed. 
They can be useful for attracting attention (Davies et al., 1998) and communicating messages to 
people who have difficulty reading printed text (Kalsher et al., 1996), and studies demonstrate that 
warnings with a pictogram are more quickly detected than those without (Laughery et al., 1993) and 
enhance understanding and recall of verbal medical instructions (Houts et al., 1998; Katz, Kripalani, & 
Weiss, 2006).  
 
Encouragingly, positive effects of pictograms on noticing, reading and comprehension have been 
demonstrated across different age groups and literacy levels. For example, Kalsher et al. (1996) 
studied the presence and absence of pictorials on participant ratings of prescription drug label 
preference in a sample with mean age of 21.8 years. The results of the study showed that the 
standard label without pictorials was rated as less readable and noticeable, and less likely to be read 
(Kalsher et al., 1996). Further, labels containing pictorials were always preferred to the same label 
without pictorials (Kalsher et al., 1996). Replication with an elderly sample with a mean age of 72.9 
years also revealed a significant preference for pictorials on the label for the measures of likelihood of 
noticing and of reading the label (Kalsher et al., 1996). However other researchers have 
recommended that pictograms should be used as a way of reinforcing information and not as a 
primary education tool (Davies et al., 1998).  
 
2.1.2 Factors influencing compliance with warnings  
2.1.2.1 Warning characteristics  
Much research has been conducted to understand the factors that influence compliance with 
warnings. Drawing on a review by Kalsher and Williams (2006), the following sections outline the 
influential factors that research has demonstrated to be the most significant.  
Location and mode  
The location of the warning can have significant influence on behavioural compliance (Frantz, 1994). 
Warnings that are placed at the front of the package or at the start of the product instructions for use 
have been shown to be more effective and quicker to find, and reducing clutter around the warning 
has also been found to be preferable (Laughery et al., 1993).  
Colour  
Research has further demonstrated that the colour red tends to increase compliance (Braun, Sansing 
& Silver, 1994; Shaver & Braun, 2000). Research by Rudin-Brown et al. (2004) found that colour-
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coded warnings indicating the level of risk increased compliance behaviour, compared with 
monochromatic warnings.  
Content and design  
Rudin-Brown et al. (2004) investigated combinations of content and format characteristics and the 
optimal label which included colour-coded borders and pictograms was associated with greater 
behavioural compliance and usability ratings. Further, explicit procedural instructions were found to 
lead to greater compliance and risk perception than non-explicit instructions (Frantz, 1994; Laughery 
& Smith, 2006).  
2.1.2.2 Context and recipient characteristics  
Product familiarity  
There is conflicting evidence for the influence of prior experience and awareness of the product on 
warning compliance. In the recent Australian study by Mallick et al. (2007), users of benzodiazepines 
perceived significantly less risk than non-users. In Laughery’s (2006) review of literature concerning 
warning effectiveness, it was noted that research findings indicate that greater familiarity is associated 
with lower likelihood of reading and complying with warnings (Wogalter, Brelsford, Desaulniers, & 
Laughery, 1991).  
Perceived risk 
Researchers note the difficulty that lay people and experts alike have in accurately judging risk 
(Slovic, Fischhoff, & Lichtenstein, 1979). People are more likely to be cautious when perceived 
hazard levels (risk) increase (Wogalter, Young, Brelsford, & Barlow, 1999). Risk or hazard perception 
is generally considered to be a result of the interaction between two variables: likelihood of injury, and 
the severity of the potential injury (Wogalter et al., 1991). In other research, (Wogalter et al., 1999) it 
was demonstrated that severity was a more important determinant than likelihood of occurrence when 
lay people were asked to judge consumer product hazards. Research by Wogalter et al. (1991) has 
revealed that the greater the levels of perceived risk, the greater the likelihood that people will seek 
and attend to warnings. However, it has been found that people that are more familiar with a product 
or situation are less likely to read warnings, which is suggested to be a result of decreased hazard 
perception associated with the product or situation (Laughery, 2006).  
Habituation 
A phenomenon that can impede compliance with warning labels is a response known as habituation 
(Ajzen, 2002). Habituation results in the failure to attend to warnings due to overexposure (Kalsher & 
Williams, 2006). Overexposure to the warnings and the potential for habituation was a factor 
prompting France to reconsider their warning label system and instigate changes to the label design 
(AFSSAPS, 2005).  
Cost of compliance 
A review by Silver and Braun (1999) identified research demonstrating that the cost (such as time, 
resources, convenience or comfort) of compliance influences whether an individual will comply with a 
warning. Studies indicate that if an individual considers that following the warning advice will be too 
expensive, time consuming, inconvenient, or will cause too much discomfort, it will be less likely that 
they will comply (Dingus, Wreggit, & Hathaway, 1993).  
Recipients 
The characteristics of the predominant users of certain medication can influence the effectiveness of 
safety information and warnings relating to medicines. It is noted that chronically ill patients and the 
elderly are more likely to experience medication errors as they take more prescription drugs than 
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younger and healthier patients (Wolf & Cooper Bailey, 2007). It is important for labelling to incorporate 
characteristics that are likely to enhance reading and comprehension, and thus compliance, within the 
user group. Information about medications is most commonly given verbally; however, according to a 
study by Houts et al. (1998) only 14% of verbal instructions are remembered. To overcome the 
inherent shortfalls of verbally counselling patients, written information is used as a supplement, and 
warning labels play an important role in this strategy. 
 
2.2 METHOD: BASELINE SURVEY 
 
The study was designed to investigate consumer perceptions of the Australian and French warnings 
and identify any benefits of adopting characteristics of the French warning approach in Australia. 
Through baseline and follow-up surveys of public hospital outpatients in Queensland, Australia, 
information was obtained from a sample of a high-level medication user group about their driving, 
medication use, perceptions of the Australian and French warnings, knowledge, risk perceptions and 
driving behaviour after taking a medication that displayed a warning label. This section outlines the 
method and results related to the baseline survey of hospital outpatients, while Section 3 outlines the 
method and results related to the follow-up survey. 
 
Purposive sampling was used to recruit outpatients who accessed the Pharmacy Services of a 
Brisbane public hospital to the study. The recruitment procedure utilised in the study was trialled and 
developed during a pilot study. Participants were screened by asking if they drove regularly (at least 
once a week). Drivers were needed to provide accurate information about decisions and intentions to 
drive while taking potentially impairing medications. People who did not drive regularly and those who 
were less than 18 years of age were excluded from participating in the study. No incentive for 
participation was offered. A total of 1070 people were identified as potential recruits to the study. Of 
these, 358 people participated in the study, giving a response rate of 33.5%.  
 
The materials used in this study consisted of a written baseline questionnaire, developed by the 
researchers specifically for the study. The baseline questionnaire depicted both the Australian and 
French warning labels, with English translations of the French warnings provided for use in Australia.  
 
2.2.1 Questionnaire constructs  
2.2.1.1 Participant demographic, driving behaviour, and alcohol and illicit 
drug use 
Demographic information included age group, gender, employment status and education level. 
Information about the individuals’ driving habits was obtained by asking whether they drove regularly, 
whether they needed to drive to and from work and as part of their professional duties, what they 
drove for their professional duties, licence class held, and estimates of the number of annual 
kilometres driven and number of hours driven in an average week. Information was also collected on 
alcohol and illicit substance use.  
2.2.1.2 Medication use 
Medication use was included to enable evaluation of the intentions and behaviour of people who were 
taking medications that display a warning about driving. Participants were asked to list the name, 
dose and frequency of medications taken in the last seven days. They were also asked to indicate the 
class(es) and frequency of medications taken in the last 12 months. Participants were also asked 
“Have you ever taken a medication that could affect your driving?” 
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The reported medications were classified using the MIMS Online Database according to their 
medication class. The active ingredient of each medication was identified so that the relevant ancillary 
warning label that would appear on the medication (according to Australian guidelines) could be 
identified and used as the basis for further analysis (e.g., warning label recall). 
2.2.1.3 Visual impact of warning characteristics 
Participants were asked to signify the level of visual impact that each of the individual characteristics 
of the Australian and French warning labels had for them on a 3-point scale where 1 = low, 2 = 
medium, and 3 = important. Participants were also asked to indicate which label characteristic was 
the most important for them. The characteristics were identified as text size, colour, pictogram, 
readability, size of warning, triangle shape. 
2.2.1.4 Recall of warnings 
Participants’ recall of warnings was assessed by asking two items, “Have you already seen a warning 
about driving on certain medication boxes?” and “Which warning do you remember seeing most 
recently on the box of your medication?” Participants indicated which of the warning labels pictured 
they recalled. These items were used as a measure of whether people noticed and remembered the 
warnings on their medications. In this case the relevant warning on the medication prescribed was 
used as the reference.  
2.2.1.5 Risk perceptions associated with the warning labels 
Personal perceptions of the risk of driving after taking a specific medication were used in comparison 
with a general risk assessment. To obtain a measure of comparisons of risk perceptions for different 
labels, risk perceptions specific to the French Level 3 warning label and the Australian mandatory 
label were assessed by items such as “How impaired do you think your ability to drive would be after 
taking a medication that displayed Label C?” and “What do you think is the chance of having a crash 
after consuming a medication which displays Label C?” To capture variations in the strength of the 
response, the items were recorded on 10-point Likert-format scales, where 1 reflected low levels of 
strength and 10 represented the highest level of strength.  
2.2.1.6 Knowledge  
Knowledge of the potential effects of medication and illicit drugs on driving was assessed by eight 
items including “The risk of having an accident does not change when you take more than the 
prescribed dose of a medication”, “Combining medications can exacerbate the effects of medications 
on driving”, “Alcohol can exacerbate the effects of certain medications on driving”. Responses to the 
items were ranked on a 4-point continuous scale where 1 = agree and 4 = disagree. The items were 
developed and structured with the assistance of medical doctors and pharmacists. 
2.2.1.7 Behavioural intentions to comply with warning advice 
General intentions to drive while potentially affected by medication were assessed by nine items in 
response to the question “If you were prescribed a medication displaying the strongest warning about 
risk for driving, what would you be likely to do?” Participants indicated the likelihood of a given 
response on a 5-point continuous scale where 1 = very unlikely and 5 = very likely. Intentions were 
also assessed by seven response items for the question “What do you intend to do if you take a 
medication with a warning that advises you not to drive?” Participants indicated agreement with each 
intention statement on a 10-point Likert-type scale where 1 = strongly disagree and 10 = strongly 
agree. Intentions specific to the strongest French warning label and the strongest Australian warning 
label were assessed by seven associated items after being asked “If you were prescribed a 
medication displaying Label [x], what would you be likely to do?” in relation to each label. Responses 
included options to follow or not follow the advice, change their driving (e.g., driving when traffic was 
less heavy), modify their medication/dose/time, and consult a doctor or pharmacist. Participants 
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indicated the likelihood of the intention on a 10-point Likert-format scale where 1 = very unlikely and 
10 = very likely.  
2.3 RESULTS: BASELINE SURVEY 
2.3.1 Participant demographic, driving behaviour, and alcohol and 
illicit drug use 
 
Participants reported their gender and age (by age group). The sample consisted of slightly more 
males (n = 186) than females (n = 165) and just over a quarter were aged between 51 and 60 years 
(26.5%). The majority (64.8%) were aged between 41 and 70 years. The median age was 53.2 years. 
Two-fifths of the participants (40.6%) had attained a Senior High School Certificate, which is less than 
the current Queensland high school retention rate (79.4% Year 7/8 to Year 12) cited by the Australian 
Bureau of Statistics (2010). The proportion of the sample who had a bachelor degree or above was 
17.5%, which is slightly lower than the Queensland state proportion for 2009 of 22% of those aged 25 
– 64 years) (ABS, 2010). Just over half of the total number of participants (54.1%) was engaged in 
either full-time or part-time employment. This is lower than the Australian labour force participation 
rate of 65.4% for the same time period (ABS, 2010). 
 
As the current Australian ancillary labels warn about possible increased impairment due to alcohol 
(Label 1) and instruct the user to avoid alcohol (Label 1a), data on the frequency (categorised as 
daily, occasionally, and rarely/never) of alcohol consumption among the sample was recorded. Most 
participants (56.1%, n = 188) reported drinking alcohol on an occasional basis. Approximately 35% (n 
= 117) reported never or rarely drinking alcohol. Nine per cent (n = 30) reported drinking alcohol on a 
daily basis, which is slightly higher than National Drug Strategy Household Survey (NDSHS) data 
(8.1% of persons aged 14 years and over) (Australian Institute of Health and Welfare [AIHW], 2008). 
 
Participants were asked about the frequency of their illicit drug (cannabis, cocaine, ecstasy and 
heroin) consumption. Table 5.3 reports illicit drug use among the survey respondents. While illicit drug 
use in the sample was lower than national drug use statistics reported in the 2007 NDSHS, the 
pattern of use was consistent (AIHW, 2008). As with the NDSHS data, the most common was the 
occasional use of cannabis (n = 20, 6%), followed by occasional use of ecstasy (n = 8, 2.4%) and 
cocaine (n = 4, 1.2%). Cannabis was the only drug reported to be used daily, by 4 participants (1.2%). 
 
Information was obtained from the sample on aspects of driving activities, including frequency of 
driving, license held, and vehicle type driven. The majority of the sample (97.5%) drove regularly (at 
least once a week). Of these, 28.1% reported that they drove to and from work, and a slightly smaller 
number reported that they drove to and from work and also for their work activities. The majority of the 
sample (87.6%) reported holding a car license, and a smaller number reported holding a heavy 
vehicle license, followed by a motorcycle license. These categories were not mutually exclusive. The 
majority of those who drove in association with work drove an automobile. 
 
Cross tabulations were conducted to explore the demographic characteristics and alcohol and illicit 
drug use of individuals on the basis of their daily use of medication, either unlabelled or labelled with 
Label 1 or Label 12 (Label 1a was omitted from analysis as it appeared only a small number of times 
– refer Table 8).  
 
 Pearson’s chi square tests of significance were used to determine the presence of any significant 
differences between the groups based on the selected demographic and substance consumption 
characteristics. The results of the analyses are provided in Tables 3 and 4. According to the analyses, 
individuals who took any medication on a daily basis that displayed Label 1, or Label 12, or no 
ancillary label warning about driving, did not significantly differ from each other according to 
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characteristics of gender, age, education attainment, work status, driving activity, alcohol consumption 
or illicit drug use.  
 
Table 3 
Demographic characteristics of Australian hospital outpatients who take medication on a daily basis 
  Label category   
Variable  
Label 1 
daily 
 
  
Label 12 
daily 
 
  
Neither label 
daily 
 χ2 
         
Gender        χ2(2) = 
0.32, p = 
.851 Male 25 (50.0%)  64 (54.7%)  97 (52.7%)  
Female 25 (50.0%)  53 (45.3%)  87 (47.3%)   
Age        χ2(6) = 
8.23, p = 
.220 18 – 30 7 (14.0%)  10 (8.3%)  29 (15.5%)  
31 – 50 12 (24.0%)  44 (36.7%)  56 (29.9%)   
51 – 60 11 (22.0%)  35 (29.2%)  49 (26.2%)   
61+ 20 (40.0%)  31 (25.8%)  53 (28.3%)   
Education        χ2(6) = 
5.61, p = 
.468 Primary 1 (2.0%)  7 (5.8%)  8 (4.3%)  
Secondary 23 (46.9%)  50 (41.7%)  93 (50.0%)   
Certificate/Dip 14 (28.6%)  45 (37.5%)  52 (28.0%)   
University 
(Bachelor, 
Postgrad) 
11 (22.4%)  18 (15.0%)  33 (17.7%)   
Work        χ2(4) = 
2.59, p = 
.628 Full-time 15 (30.6%)  38 (31.7%)  66 (35.9%)  
Part-time 9 (18.4%)  22 (18.3%)  41 (22.3%)   
Do not work 25 (51.0%)  60 (50.0%)  77 (41.8%)   
Driving        χ2(4) = 
8.89, p = 
.064 Yes (to and 
from work and 
for work 
activities) 
23 (46/9%)  55 (45.5%)  107 (57.5%)  
No 6 (12.2%)  21 (17.4%)  14 (7.5%)   
Do not work 20 (40.8%)  45 (37.2%)  65 (34.9%)   
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Table 4 
Alcohol and illicit drug use of Australian hospital outpatients who take medication on a daily basis 
  Label category   
Variable  
Label 1 
daily 
 
  
Label 12 
daily 
 
  
Neither label 
daily 
 χ2 
         
Alcohol use        χ2(4) = 
7.82, p = 
.098 Never 19 (39.6%)  40 (34.8%)  42 (24.4%)  
Occasionally 23 (47.9%)  65 (56.5%)  116 (67.4%)   
Daily 6 (12.5%)  10 (8.7%)  14 (8.1%)   
Cannabis usea       - 
Never 43 (91.5%)  108 (94.7%)  145 (84.8%)   
Occasionally 4 (8.5%)  6 (5.3%)  22 (12.9%)   
Daily 0  0  4 (2.3%)   
Cocaine usea       - 
Never 45 (93.8%)  112 (98.2%)  164 (96.5%)   
Occasionally 6 (6.3%)  2 (1.8%)  6 (3.5%)   
Daily 0  0  0   
Ecstasy usea       - 
Never 44 (91.7%)  112 (98.2%)  162 (94.7%)   
Occasionally 4 (8.3%)  2 (1.8%)  9 (5.3%)   
Daily 0  0  0   
Heroin usea       - 
Never 45 (95.7%)  114 (100%)  170 (99.4%)   
Occasionally 2 (4.3%)  0  1 (0.6%)   
Daily 0  0  0   
         
a Cells have expected frequencies less than 5. 
  
  Page | 16 
2.3.2 Medication use 
 
The reported medications were grouped according to their medication class as listed in the MIMS 
medications database. A total of 1214 medications were reported and 9% of these were unable to be 
identified. On average people reported taking four different medications in the last seven days, and 
the number of medications ranged from one to 14 medications per person. A total of 78 medication 
classes made up the total 1107 classified  medications used by the sample in the last seven days. 
Table 5 provides the complete list of medication classes reported being used by the sample within the 
last seven days prior to the survey. The frequency of medication classes used by the sample that 
potentially represent a risk for driving impairment and may display a warning label is highlighted in 
bold. The medications reported most frequently belonged to the Antihypertensive Agents and 
Immunomodifiers medication classes. Medications belonging to the Adrenal Steroid Hormones, 
Hyperacidity, Reflux and Ulcers and Simple Analgesics and  Antipyretics classes were also frequently 
reported.  
Table 5  
Frequency of 78 MIMS medication classes taken in last 7 days 
MIMS medication class Frequency Per cent 
Adrenal steroid hormones 70 6.3 
Agents affecting calcium and bone metabolism 26 2.3 
Agents used in drug dependence 3 0.3 
Agents used in gout and hyperuricaemia 13 1.2 
Alkylating agents 1 0.1 
Aminoglycosides 2 0.2 
Anorectic and weight reducing agents 1 0.1 
Antiangina agents 20 1.8 
Antianxiety agents 6 0.5 
Antiarrhythmic agents 2 0.2 
Anticoagulants, antithrombotics 19 1.5 
Anticonvulsants 33 2.5 
Antidepressants 47 3.6 
Antidiarrhoeals 5 0.4 
Antiemetics, antinauseants 1 0.1 
Antifungal agents 3 0.3 
Antihistamines 9 0.8 
Antihypertensive agents 107 9.7 
Antihypertensive agents/antiangina agents 7 0.6 
Antimetabolites 10 0.9 
Antimigraine preparations 2 0.2 
Antipsychotic agents 6 0.5 
Antirheumatoid agents 4 0.3 
Antituberculotics and antileprotics 6 0.5 
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Antiviral agents 18 1.6 
Beta-adrenergic blocking agents 34 3.1 
Bladder function disorders 3 0.3 
Bronchodilator aerosols and inhalations 2 0.2 
Bronchospasm relaxants 4 0.4 
Cephalosporins 2 0.2 
Combination simple analgesics 7 0.6 
Detoxifying agents, antidotes 3 0.3 
Digestive supplements and cholelitholytics 3 0.3 
Diuretics 22 2.0 
Emollients, antipruritics and protective 
preparations 
1 0.1 
Erectile dysfunction agents 1 0.1 
Expectorants, antitussives, mucolytics, 
decongestants 
1 0.1 
Fat soluble vitamins 20 1.8 
General well-being, multiple use preparations 3 0.3 
Glaucoma preparations 1 0.1 
Gonadal hormones 9 0.8 
Haemopoietic agents 5 0.4 
Herbal analgesics and anti-inflammatories 6 0.5 
Hormonal antineoplastic agents 1 0.1 
Hyperacidity, reflux and ulcers 72 6.5 
Hypoglycaemic agents 30 2.7 
Hypolipidaemic agents 67 6.1 
Immunomodifiers 104 9.4 
Infant formulas 1 0.1 
Insulin preparations 11 1.0 
Iron 7 0.6 
Laxatives 4 0.4 
Macrolides 3 0.3 
Mens’ supplements 1 0.1 
Movement disorders 3 0.3 
Multivitamins and minerals 62 5.6 
Muscle relaxants 3 0.3 
Narcotic analgesics 47 4.2 
Neuromuscular agents 1 0.1 
Noncytotoxic and supportive therapy 1 0.1 
Nonsteroidal anti-inflammatory agents 16 1.4 
Ocular decongestants, anaesthetics, anti- 1 0.1 
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inflammatories 
Other antibiotics, anti-infectives 16 1.4 
Other antineoplastic agents or immunomodifiers 1 0.1 
Other respiratory agents 1 0.1 
Penicillins 4 0.4 
Peripheral vasodilators 1 0.1 
Pituitary hormones 3 0.3 
Preventative aerosols and inhalations 5 0.4 
Psoriasis, seborrhoea and ichthyosis 1 0.1 
Quinolones 1 0.1 
Sedatives, hypnotics 5 0.4 
Simple analgesics, antipyretics 68 6.1 
Tetracyclines 1 0.1 
Thyroid hormones and antithyroid agents 13 1.2 
Topical nasopharyngeal medication 1 0.1 
Topical ocular anti-infective preparations 2 0.2 
Topical ocular steroid preparations 1 0.1 
   
 
2.3.2.1 Prescription medication class use in last 12 months 
Participants were asked to report their consumption of selected classes of prescription drugs (i.e., 
sedatives, tranquillisers or anti-anxiety medication, antidepressants, antihistamines or anti-allergy 
medication, analgesics, anticonvulsives, or other drugs for mental health) in the 12 months prior to the 
survey. These classes were selected on the basis of the earlier literature review findings in which 
these medication classes are implicated for potential driving impairment. Nearly three quarters of the 
358 respondents (73.2%, n = 262) reported that they had taken at least one of these classes of 
medication in the last 12 months. The majority (58.4%, n = 209) reported having taken at least one 
class on an occasional basis, while a third of the sample (33.5%, n = 120) reported taking at least one 
class of medication on a daily basis. Frequency of daily and occasional use in the last 12 months of 
each surveyed medication class is presented in Table 6. As indicated in the table in bold, 
antidepressants and analgesics were the most common drug types to be consumed on a daily basis, 
and analgesics and antihistamines/anti-allergy drugs were the most common drug types to be taken 
occasionally. Sedatives were almost as likely as antihistamines to be used occasionally.  
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Table 6 
Selected medication class – daily and occasional use in the last 12 months 
  Medication 
  Daily  Occasionally 
Medication class  n %  n % 
       
Sedatives  9 2.5  65 18.2 
Tranquillisers or  
anti-anxiety 
 20 5.6  16 4.5 
Antidepressants  58 16.2  9 2.5 
Antihistamines or  
anti-allergy 
 15 4.2  77 21.5 
Analgesics   57 15.9  158 44.1 
Anticonvulsives  10 2.8  1 0.3 
Other (for mental health)  12 3.4  7 2.0 
Total  120 33.5  209 58.4 
   
 
Of the people who took medications in the last 12 months, 43.9% reported having ever taken one 
class of medication in the last 12 months, while 56.1% participants took more than one class of 
medication. Table 7 presents the number of classes of prescription medication taken daily in the 12 
months prior to the survey. Most commonly, only one class of medication was taken on a daily basis.  
Table 7 
Number of selected classes of prescription medication taken daily in last 12 months 
  Daily 
Number of medication 
classes 
 n % 
    
One class  80 66.7 
Two classes  22 18.3 
Three classes  15 12.5 
Four classes  3 2.5 
    
Total  120 100 
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2.3.2.2 Prevalence of warning labels on medications taken in last seven days 
All reported medications were classified according to their associated ancillary warning label, as 
stipulated by the APF guidelines (PSA, 2006). According to the analysis, Label 12 was the most 
common label that would be expected to appear on medications used by the sample. Of those who 
reported using prescription medication in the last seven days prior to the survey, 25.4% (n = 78) had 
taken at least one medication on which Label 1 would appear, 2.9% (n = 9) had taken at least one 
Label 1a medication, and 55% (n = 169) had taken at least one Label 12 medication. Table 8 displays 
the labels and frequency of appearance that should occur on the medications used by the sample in 
the seven days prior to the survey. 
 
Table 8 
Frequency of Labels 1, 1a and 12 on medications used in the 7 days prior to survey 
  Daily 
Warning label  n % 
    
Label 1    
 
 
 78 25.4 
Label 1a    
 
 
 9 2.9 
Label 12    
 
 
 169 55.0 
    
Note. Ancillary Labels pictured are actual size. 
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2.3.3 Visual impact of warning characteristics 
 
Participants were asked to signify the level of visual impact that individual characteristics of the 
warning labels held for them. Of the characteristics rated as having high importance, the size of the 
warning label was most frequently identified as having high importance (74.7%). Text size was the 
next most frequently identified (70.4%), followed by red colour (69.1%), picture of car (50.8%) and 
triangle shape (50.2%) were rated of equal importance and finally the yellow colour (34%). The 
orange colour was regarded as of least importance (19.4%). Table 5 presents the frequency of the 
perception of characteristics as having high importance. Participants were also asked to identify the 
most important characteristics. Most frequently, participants indicated that using a combination of 
elements held the most impact (37.2%), followed by the colour of the warning (20.4%). Table 9 
displays the results. 
 
Table 9 
Australian hospital outpatients’ ratings of impact of warning label visual characteristics 
 Frequency 
Warning characteristic rated as 
having high importance/impact 
n % 
Orange colour 61 19.4 
Yellow colour 111 34.0 
Triangle shape 165 50.2 
Pictogram 169 50.8 
Red colour 228 69.1 
Text size 231 70.4 
Size of label 245 74.7 
   
 
 
In relation to individual ratings of the ease of reading the Australian and French warning labels, 
participants most frequently rated the Australian Label 1 as being the easiest warning to read (37%), 
followed by the French Level 1 (yellow) label. The most difficult to read were the Australian Label 12 
and the French Level 2 labels. Table 10 presents the ratings for all warning labels. 
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Table 10 
Australian hospital outpatients’ ratings of easiest warning to read 
  Frequency 
Warning label  n % 
Australian labels    
 
 121 37.3 
 
 
 47 14.5 
 
 22 6.8 
French labels    
 
 
 80 24.7 
 
 
 19 5.9 
 
 
 35 10.8 
Valid Total  324 90.5 
Missing  34 9.5 
Total  358 100 
    
Note. Labels pictured in the table are not actual size. 
 
 
2.3.4 Recall of warnings  
2.3.4.1 Label recall according to number of medication classes consumed 
 
The frequency of warning label recall among those who had taken at least one medication was 
analysed according to the number of medication classes consumed. Label recall in general was high 
but was found to differ according to the number of classes of medication taken. The lowest rate of 
recall (85.9%) occurred when people were taking only one class of medication. This increased to 
approximately 93% when taking two and three classes of medication, but then decreased to 
approximately 91% when taking four classes of medication. For those people who took five or more 
classes of medications, there was 100% recall of a warning about driving. Table 11 shows the 
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frequency of recall of warning labels among participants who had taken at least one medication in the 
seven days prior to the survey. Table 12 presents the recall of a warning label about driving by 
number of classes of medication. 
 
Table 11 
Australian hospital outpatients’ frequency of recall of warning label among participants who had taken 
at least one medication in last seven days 
 Taken at least one 
medication 
Recall of warning about driving n % 
 
Yes 162 89.5 
No 18 9.9 
Valid Total 180 99.4 
Missing 1 0.6 
Total 181 100 
   
 
Table 12 
Australian hospital outpatients’ recall of warning label according to number of classes of medications 
taken 
Number of 
medication 
classes 
 Recall of warning 
 Yes  No  Total 
 n %  n %  n % 
          
One class  67 85.9  11 14.1  78 100 
Two classes  49 92.5  4 7.5  53 100 
Three classes  26 92.9  2 7.1  28 100 
Four classes  10 90.9  1 9.1  11 100 
Five classes  8 100  0 0  8 100 
Six classes  2 100  0 0  2 100 
         
 
  
  Page | 24 
2.3.4.2 Label recall according to label type on medication used in last seven 
days 
 
The majority of participants (89.6%) who reported receiving medication with Label 1 in the last seven 
days recalled seeing the label on their medication, with eight people (10.4%) unable to recall the 
label. Similarly, the majority of participants (87.8%) who received only medication displaying Label 12 
were able to recall the label, while 12.2% were unable to recall the label. Table 13 presents the 
frequency of label recall among those who received a medication that according to the APF (PSA, 
2006) guidelines would be labelled with Label 1 (including those who received a combination of 
medications labelled with Label 1, 1a, and 12). 
 
Table 13 
Australian hospital outpatients’ frequency of medication warning label recall according to warning 
label type, for medications used in last seven days 
 Medication 
 Label 1 Label 12 
Already seen warning 
label about driving? 
n % n % 
     
Yes 69 89.6 108 87.8 
No 8 10.4 15 12.2 
     
Total 77 100 123 100 
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2.3.5 Attitudes measured by risk perceptions associated with the 
warning labels  
 
Attitudes as measured by risk perceptions were assessed by asking participants to indicate which 
warning label they perceived as carrying the strongest message of risk. The French Level 3 (red) 
label was most commonly (51.2%) perceived to have the strongest message of risk. The Australian 
Label 1 was the second most frequently rated at a much lower 22.2%. The results for perceptions of 
all warning labels are shown in Table 14. 
Table 14 
Australian hospital outpatients’ perceptions of which warning conveys the strongest message of risk 
 Frequency 
Warning label n % 
Australian labels   
 
74 22.2 
 
36 10.8 
 
15 4.5 
French labels   
 
 
21 6.3 
 
 
17 4.7 
 
 
171 51.2 
   
Valid Total 334 93.3 
Missing 24 6.7 
Total 358 100 
Note. Labels pictured in the table are not actual size. 
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Risk perceptions for the French (Level 3) and Australian (Label 1) warning labels were further 
assessed by asking participants about their perceptions of impairment and the chance of being 
involved in a crash. Perceptions of impairment were assessed by asking “How impaired do you think 
your ability to drive would be after taking a medication that displayed Label [x]?” Responses were 
recorded on a 10-point Likert-type scale with 1 = slightly impaired and 10 = very impaired. Participants 
most frequently indicated that they thought that they would be moderately impaired (27.7%) after 
taking a medication that displayed the Australian label (Label 1). With the same question repeated but 
referring to the French label (Level 3), participants most frequently perceived that they would be very 
impaired (69.2%). A Wilcoxon Signed Rank test revealed that the difference between perceptions of 
possible impairment were significantly stronger for the French label, z = -13.26, p < .001 (n = 325), 
with a large effect size (r = .52), according to Cohen’s (1996) criteria.  
 
The chance of being involved in a crash was measured by asking “What do you think is the chance of 
having a crash after consuming a medication which displays Label [x]?” with responses indicated on a 
10-point Likert-type scale where 1 = very unlikely and 10 = very likely. For the Australian label (Label 
1), participants most frequently perceived their chance of being in a crash as likely (37.5%). 
Repeating the same question for the French label (Level 3), participants most frequently perceived 
their chance of being in a crash as very likely (56.4%). A Wilcoxon Signed Rank test revealed that this 
difference was also significant, z = -11.87, p < .001 (n = 322), with a large effect size (r = .46) 
according to Cohen’s (1996) criteria.  
 
2.3.6 Knowledge about effects of certain medications and substance 
combinations on driving 
 
Knowledge was assessed by asking participants to respond with the extent to which they agreed or 
disagreed with a list of general statements about effects and use of medications, other substances, 
and combinations of these. Responses were recorded on a 4-point scale, and recoded into two 
categories (responses 1 – 2 = agree, and responses 3 – 4 = disagree), and the frequencies are 
displayed in Table 15. Correct responses are indicated by an asterisk. The overwhelming majority 
(90% or more) of participants gave the correct answer to most items. Just over one fifth (21.8%) 
incorrectly believed that the risk of having an accident does not change when taking more than the 
prescribed dose of a medication. A similar proportion (23.2%) incorrectly believed that risk of having 
an accident is weaker at the beginning of treatment.  
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Table 15 
Australian hospital outpatients’ knowledge about the effects of medications, alcohol, illicit drugs and 
driving 
Knowledge statement  Disagree (%) Agree (%) 
    
Discontinuing any medication without the advice 
of your doctor can be harmful to your health 
 8.7 91.3a 
A sudden discontinuation of your medication can 
be harmful to your health 
 7.2 92.8a 
The risk of having an accident does not change 
when you take more than the prescribed dose of a 
medication 
 78.2a 21.8 
Combining medications can exacerbate the 
effects of medications on driving 
 8.9 91.1a 
The risk of having an accident is weaker at the 
start of treatment than during long term treatment 
 76.7a 23.2 
Alcohol can exacerbate the effects of certain 
medications on driving 
 4.5 95.5a 
Driving under the influence of alcohol is 
dangerous 
 2.4 97.6a 
Driving under the influence of cannabis is 
dangerous 
 4.5 95.5a 
    
a Correct answer. 
 
2.3.7 Behavioural intentions to comply with warning advice  
 
Participants’ intentions to comply with the advice of the strongest warning labels in both Australia 
(Label 1) and France (Level 3) were explored by asking participants to rate the likelihood of numerous 
behavioural options. Participants were asked “If you were prescribed a medication displaying Label 1, 
what would you be likely to do?” and responses for each behavioural option were recorded on a 10-
point Likert-type scale where 1 = very unlikely and 10 = very likely. For simplicity the responses were 
recoded into categorical variables where 1 – 5 = unlikely and 6 – 10 = likely. The differences in 
intentions related to the Australian and French warning labels were tested for significance using 
McNemar chi square for paired samples. There were no differences in regard to driving when the 
traffic was less heavy or not taking the medication so that they could drive. All other differences were 
significant with the stronger effect being observed for the French label. Table 16 shows the responses 
for this item. 
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Table 16 
Australian hospital outpatients’ intentions  
 
  
 Australian Label  
(Label 1) 
French Label  
(Level 3) 
  
 
  
  
 Likely Unlikely Likely Unlikely   
Response n % n % n % n %  χ2 
           
Consult doctor 
or pharmacist 
225 62.8 108 30.2 292 81.6 40 11.2  χ2(1) = 55.14, 
p < .001 
Modify 
medicine so 
can continue to 
drive 
135 37.7 190 53.1 93 26.0 225 62.8  χ2(1) = 15.84, 
p < .001 
Wait some time 
before driving 
177 49.4 150 41.9 124 34.6 197 55.0  χ2(1) = 16.66, 
p < .001 
Drive when 
traffic less 
heavy 
75 20.9 248 69.3 60 16.8 260 72.6  χ2(1) = 2.42, p 
= .120 
Not drive 163 45.5 161 45.0 248 69.3 84 23.5  χ2(1) = 51.13, 
p < .001 
Not take the 
medication 
47 13.1 275 76.8 39 10.9 282 78.8  χ2(1) = 0.65, p 
= .418 
Take 
medication and 
not drive 
194 54.2 133 37.2 261 72.9 68 19.0  χ2(1) = 41.37, 
p < .001 
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3 STUDY 2: FOLLOW-UP SURVEY 
3.1 INTRODUCTION 
3.2 METHOD 
 
A follow-up telephone survey was conducted with a subgroup of consenting participants who reported 
at the baseline survey to be taking at least one medication that required an ancillary warning label 
about driving impairment. From the total sample of 358 participants, 176 participants gave their 
permission and telephone contact details for participation in a follow-up telephone survey, and of 
these, 67 participants were not followed up as analysis revealed that they were not taking medication 
that would be expected to have a warning label about driving impairment. The remaining 109 
participants were contacted by telephone to participate in the follow-up study. A maximum of four 
attempts to contact participants was made. If after the fourth attempt the person was unreachable, no 
further attempts were made to contact them. A total of 53 (48.62%) participants completed the follow-
up survey. 
3.2.1 Questionnaire constructs: Follow-up survey   
A questionnaire was developed for the follow-up study of the outpatients which was designed to 
obtain self-report information on actual behaviour in response to the medication warnings about 
driving. The questionnaire was administered in a telephone survey with individual participants, and 
used a mix of open-ended questions with closed response questions. In the present research context, 
behaviour initiative refers to avoiding driving if an effect on driving ability was noticed, in accordance 
with the Australian warning label advice. The questionnaire assessed any changes to medication use 
since the baseline survey, behavioural responses to medication warning advice, information seeking, 
self-assessment of impairment, and understanding of the terms used in the ancillary warning labels. 
3.2.1.1 Driving and medication 
Participants were first asked if they had still been driving since the last survey, and if they were still 
taking the same medication. Any changes in medication use were recorded. Changes in driving due 
to medication use were assessed by asking “If you are no longer driving, is that because of any of the 
medication you told us about or because your driving was affected?”, and “Can you please describe 
what it was that happened that made you stop driving?” with participant comments recorded as 
necessary. Participants were also asked “Did you ever have to think about whether you could drive 
while you were taking this medication?” with responses recorded as either Yes or No.  
3.2.1.2 Warning labels 
Warning label recall was assessed by two items, “Do you recall seeing any warning label about 
driving on any of the medications that you told us about?” and  if applicable, “What did the warning 
label say?” Responses in the participants’ own words were recorded. Aspects of the decision to drive 
were investigated with the items “Did you think about the warning when you made your decision about 
driving?” and “Did you follow the advice on the warning label?” Response options were Yes, No, Do 
not recall, and Not applicable, which were used to encapsulate all foreseeable circumstances of the 
participant. 
3.2.1.3 Response to advice  
Following the advice about driving impairment was assessed by four items, “Did you read the 
information leaflet inside any of your medication boxes?” (response options included Yes, No, Do not 
recall, No medication leaflet, and Not applicable), “Did you follow the advice on the leaflet inside any 
of your medication boxes?” (response options included Yes, No, Do not recall, Other, and Not 
applicable), “Did you follow the advice of your doctor about driving?” (response options included Yes, 
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No, Do not recall if advice given, Do not recall if advice followed, and Not applicable), and “Did you 
follow the advice of your pharmacist about driving?” (response options included Yes, No, Do not recall 
if advice given, Do not recall if advice followed, and Not applicable).  
3.2.1.4 Behavioural responses 
Behavioural responses were explored by using ten items that included possible behavioural options in 
response to taking medication that displayed a warning about driving. The response options for all the 
items included Yes, No, Do not recall, Other, and Not Applicable, to encapsulate all possible 
circumstances of the participant. If a participant answered “other”, they had the option of giving their 
specific response otherwise unlisted, which the Research Officer recorded verbatim. The items were:  
1. Did you take the medication as directed and drive as usual?  
2. Did you avoid driving because you noticed an effect on your driving ability? 
3. Did you modify the way you took the medication (e.g., the dose, the time) so that you 
could continue to drive? 
4. Did you change when or where you drove (e.g., when or where there was less traffic)? 
5. Did you decide not to take the medication at all so that you could continue to drive? 
6. Did you not take the medication because you had to drive?  
7. Did you drive only when you thought the medication didn’t affect you anymore? 
8. Did you take the medication and not drive? 
9. Did you ask your doctor or pharmacist only after you noticed an effect of the 
medication?  
10. Did you reduce the amount of alcohol you drank while taking the medication?  
 
  
  Page | 31 
3.3 RESULTS 
3.3.1 Behavioural responses to taking medication that can impair 
driving 
 
The follow-up survey data was examined to explore participants’ behavioural responses to taking a 
medication that displays a warning about driving (see Table 17). Of those who completed the follow-
up survey and reported at follow-up taking at least one medication that required an ancillary warning 
label about driving impairment (n = 53), only just over half (51%, n = 27) reported that they recalled 
seeing a warning label about driving on at least one of their medications. Of these, 70% reported that 
they had thought about the warning when they made their decision about driving and three quarters 
(78%) reported that they followed the advice on the warning label.  
 
Table 17 
Follow-up of hospital outpatients’ behavioural responses to taking medication that displayed a 
warning label (N = 53) 
   Frequency 
   Yes  No 
Response   n %  n % 
        
Took medication and drove as usual   42 79.4  10 18.9 
Modified the medication (e.g., dose, 
time) so could continue to drive 
  9 17.0  42 79.2 
Changed when or where drove (e.g., 
when there was less traffic) 
  8 15.1  42 79.2 
Did not take medication so could 
continue to drive 
  5 9.4  47 88.7 
Reduced alcohol intake while taking 
medication 
  11 20.7  10 18.9 
        
Note. Number excludes participants who answered ‘other’ or ‘does not apply’. 
 
 
Ability to detect impairment and confidence in the accuracy of self-assessment of impairment was 
assessed with two items. Participants were asked “Do you think you would be able to tell if you were 
affected [by your medication]?” and “How confident are you that your judgment would be correct?” Of 
the 53 participants that responded to these items, the majority (88.7%) thought that they would be 
able to tell if they were affected (through their own assessment), and were very confident (M = 8.09, 
SD = 1.58, where 10 = very confident) in the accuracy of their judgment. 
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4 STUDY 3: HEALTH PROFESSIONALS 
4.1 INTRODUCTION 
 
This study aimed to investigate health professionals’ perceptions of the Australian and French 
warning labels. This report provides information from French Doctors and Pharmacists (as prescribers 
and dispensers of medicines) on the medication labels. As noted earlier the research team has 
experienced considerable difficulty completing the originally proposed study to conduct focus groups 
with Australian Health professionals. To date this component remains incomplete and this report only 
provides the findings of the complementary study of French Health professionals on the same issues. 
4.2 METHOD 
 
The study includes a survey of doctor and pharmacists’ perceptions of the Australian and French 
warning labels. Results draw on two surveys of French doctors’ and pharmacists’ knowledge, 
preferences, and actions in relation to the warning labels, and include their recommendations for the 
improvement of the labels. It was designed to obtain information from the perspective of health 
professionals. Specifically, it investigated the following issues: 
 
 Perceived visual impact of the Australian and French warning characteristics 
 Perceived need for improvements to warnings  
 Perceived advantages and disadvantages of the Australian and French warnings 
 
Participants were required to be currently practicing doctors or pharmacists in either a hospital or 
community setting in France. No incentives for participation were offered. Based on the recruitment 
rate in recent relevant research (Dubois, 2007), it was aimed to have 100 completed questionnaires 
from medical doctors (50) and pharmacists (50) in France. A total of 48 doctors (n = 33 males, n = 15 
females) aged between 30 and 70, and 50 pharmacists (n = 13 males, n = 35 females, 2 unspecified) 
currently practicing in the Region Isere, France, volunteered to participate in the study. All responses 
were anonymous and the only identifying information recorded was the age and sex of the participant.  
 
A written questionnaire and project information sheet was developed in French by the researcher 
specifically for the study. The first page of the questionnaire provided the project information sheet, 
which informed participants of the research aims, research team contacts, the nature of participation, 
and information about ethics and privacy. For participants’ reference, the questionnaire included a 
copy of all medication warning labels relating to driving currently in use in Australia and France. The 
labels were replicated to scale and colour accuracy, and the Australian warnings labels were 
translated into French. 
 
The questionnaires consisted of 18 items to assess demographics, perceptions, awareness and 
impact of the medication warning labels, as described in the research aims. To obtain greater 
understanding of the health practitioners’ experiences, both quantitative and qualitative data was 
collected. The quantitative data provided an opportunity to obtain frequencies and rankings of 
preferences, while the qualitative data consisted of open-ended questions which allowed health 
professionals to describe their experiences in detail. A sample of questions and the response format 
relating to each of the constructs is provided in Table 18. 
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Table 18 
Sample Doctor and Pharmacist questionnaire items 
 
Concept Questionnaire item Response type 
Awareness Are you aware of these pictograms and warnings? Yes/No 
Knowledge Can you name a medication or therapeutic class 
associated with each of the warnings? 
Written 
Perceptions of 
warning 
characteristics 
Which label characteristics have the strongest visual 
impact? 
Ranking 
Patient/practitioner 
interactions 
Indicate in which way the warnings have had an 
impact on the advice accompanying the prescription 
or your prescribing practice? 
If you patient saw one of these warnings on a box, 
what would your advice be? 
Written 
 
 
Likert scale 
Information needs Have you, yourself, received sufficient information to 
inform your patients? 
If not, what information and types of information 
would you like to have? 
Yes/No 
 
Written 
Recommendations Do you think the warnings need to be improved? If 
yes, please specify. 
Written 
 
The study was conducted with the assistance of colleagues at the Centre de Pharmacovigilance 
(CRPV), at the Grenoble University Hospital, France. Prior to conducting the study, ethical clearance 
was obtained from the ethics committee of both the Grenoble University Hospital and the Queensland 
University of Technology. To recruit participants, the names and addresses of all doctors and 
pharmacists of the Isère region of France were obtained from the White Pages and compiled into a 
spreadsheet. Using a randomisation function, 400 pharmacists and 1000 doctors were approached to 
volunteer to participate in the study, until the desired sample size was reached. Questionnaires sent 
from the CRPV to the practitioners, which the practitioners then completed and returned to the CRPV. 
All completed questionnaires received at the CRPV were numbered and photocopied, and forwarded 
to the researcher in Australia for data analysis. 
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4.3 RESULTS 
4.3.1 Perceptions of warning labels 
4.3.1.1 Perceived visual impact of Australian and French warning label 
characteristics 
Both individual and combinations of warning label characteristics including text, colour, pictogram and 
form were assessed by the doctors and pharmacists for visual importance. The analyses indicated 
that the characteristics selected as most important varied between the doctors and pharmacists. For 
the doctors, the colour of the warning was most frequently cited as the most important visual 
characteristic, closely followed by the pictogram. Following these, the size of the warning, the 
appearance of the triangle, and the text were perceived as being less important. By contrast, the most 
frequently cited warning characteristic of importance to the pharmacists was the pictogram, followed 
by a preference for a combination of characteristics. The colour of the warning was the next most 
visually important, followed by triangle and size (equally important). 
 
Perceptions of visual impact of warning characteristics 
The visual impact of warning labels were measured on a 3-point Likert scale where a value of 1 = ‘low 
impact’, 2 = ‘medium impact’ and 3 = ‘strong impact’. Pharmacists reported the vehicle pictogram as 
having the highest visual impact (M = 2.8, SD = .49), followed by the appearance of a triangle (M = 
2.58, SD = .61), and red colour (M = 2.50, SD = .71). Sufficient text or label size, text message, and 
colours of orange and yellow had less impact. By contrast, doctors perceived the red colour as having 
the most visual impact (M = 2.74, SD = 57), followed by the vehicle pictogram (M = 2.60, SD = .69), 
triangle shape (M = 2.47, SD = .66) and sufficient size of text or label (M = 2.40, SD = .72). Text 
message (M = 2.13, SD = .75), orange colour (M = 2.12, SD = .70) and yellow colour (M = 1.81, SD = 
.80) had the least visual impact. 
4.3.1.2 Perceived need for improvements to warnings 
Eleven doctors thought that no changes were needed, and ten of those eleven didn’t comment any 
further. One doctor commented ‘I find it well done. It allows the doctors and pharmacists to give the 
patient more explanation’. Three doctors stated they had no opinion regarding the warnings, one said 
this was due to never having seen them. Five doctors thought that the warnings and pictograms 
should be improved, but did not specify how they thought this could be done. Of the remaining 
responses suggesting that the warnings and pictograms could be improved, four distinct categories 
emerged: enhanced visibility, increased size, clarity of information, and simplification.  
 
Of those who suggested increased size, doctors commented ‘increase the size of the vehicle’, and 
‘more visible’. Another suggested ‘the pictogram should be bigger’, and another suggested the 
warnings should be bigger, such as those displayed on cigarette packets. Several doctors suggested 
simplifying the warnings by having ‘not too many things written on the box’. Several others thought the 
warnings could be improved by clarifying the message, while conversely, others thought the warnings 
required ‘improved explanations and publicity campaigns’. One doctor suggested the warning should 
‘give an idea of the delay between driving and taking the medication: e.g., do not drive during the first 
week of treatment, during 6 hours following taking a dose’. Another commented that ‘the word ‘Level’ 
is unnecessary. You could replace it with ‘caution’ or ‘danger, or, ‘attention, danger’’. 
 
Thirteen pharmacists indicated that they thought no changes needed to be made to the warnings and 
pictograms; however, the majority of the pharmacists had some suggestion for improvements. Three 
main themes emerged from those suggestions: Noticeability/visibility, simplification, and prevalence. 
These are discussed in more detail below. 
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Noticeability 
The overwhelming majority of suggestions for improvements concerned the visibility of the warnings 
and pictograms. Within this category, three sub-categories appeared.  
Size 
The largest number of comments concerned increasing the size of the warnings to make them more 
likely to be noticed by patients: ‘they must be improved to be more visible and comprehensible to the 
greatest number of people’, ‘bigger and more visible’. One pharmacist also commented on the size of 
the text: ‘Good signalisation, but the text should be more visible/readable. The large text should be 
made a little bigger’. 
Position 
Other pharmacists referred to the position of the label on medication packaging, and suggested 
placing the warning on the front of the box. 
Colour 
Pharmacists also thought that the colours of the warnings could be made to be ‘more visible’ to 
improve noticeability. Some suggested improving the colours in conjunction with placing the warnings 
more prominently on the medication packaging. 
 
Simplification 
The second most frequent theme was simplification of the warnings. Suggestions included making the 
warnings more precise. One pharmacist commented, ‘There should not be too many similar 
pictograms – this becomes a source of error. Labels 1, 2 and 3 are too close – the text is not read to 
the end!’ 
 
Prevalence 
Several pharmacists called attention to the problem of prevalence of the warnings, suggesting that the 
frequency of the appearance of the warnings could lead to the ‘banalisation’ of the message. ‘The 
pictograms should be reserved for bans or severe side effects’; ‘less frequency. There are a lot of 
Level 1 that are rarely justified and lead to a diminution in the effectiveness of the pictogram. If Levels 
2 and 3 were larger, it would have more impact on patients.’ 
4.3.1.3 Perceived advantages and disadvantages of the Australian and 
French warnings 
 
French doctors and pharmacists were asked, “What are the advantages and disadvantages of the 
warnings A, B and C (the French warnings), compared with the warnings D, E and F (the Australian 
warnings)”. The responses were categorised according to the themes raised in each response.  
 
A very strong theme emerging from the pharmacists’ responses was the concern that consumers 
would not read the Australian warnings, due to their lengthy text and the small font size. The 
pictograms used in the French approach were perceived to have much more visual impact, allowing 
the warning to be rapidly identified and attract attention, resulting in a warning that is more visible than 
the Australian warnings. In addition, the pictogram was perceived to have the advantage of conveying 
the warning message in a glance, and of being understood by everyone (for example, those who are 
illiterate, those with vision difficulties such as older drivers who may not be able to read the text), 
which was in contrast to the Australian labels. This characteristic was also seen to be an advantage 
for both health professionals and consumers in communicating information.  
 
The grading system of risk for driving was seen to be an advantage, while the Australian warnings 
were perceived by some to lack characteristics that enable viewers to distinguish between the 
warnings and their message. There were mixed perceptions of the clarity of the warnings, with some 
pharmacists perceiving the Australian warnings to be more specific than the French, while others held 
the opposite perception.  
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Similar sentiments were revealed in the responses from the sample of medical doctors. The most 
frequently occurring theme was that the use of the pictograms in the French approach was an 
advantage. The pictograms were perceived to draw attention and have immediate visual impact for 
the viewer, and again this was thought to especially benefit those with vision difficulties. The 
pictograms were also perceived to convey information easily, and to be understood without it being 
necessary to read the text. Overall, the French warnings were thought to be more memorable and 
easily understood than the Australian warnings, which were considered to contain too much text in too 
small a font to be easily read. The issue of familiarity with the French warning labels and its potential 
impact on their perceptions of visual impact could not be tested here. This remains  a possible 
confound of these findings. 
 
As with the pharmacists, there were somewhat mixed and opposing perceptions of the medical 
doctors concerning the explicitness of the Australian and French warning content. One medical doctor 
noted the caution against alcohol consumption, and considered this to be an advantage of the 
Australian warnings over the French warnings.  
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5 CONCLUSIONS AND RECOMMENDATIONS 
 
This project has critically examined the currently established Australian approach to medication 
warnings regarding potential driving impairment.  
 
A  sample (n = 358) of  hospital pharmacy outpatients recruited at a large public hospital were 
surveyed concerning their responses to the current Australian medication warning labels and to the 
recently developed French approach to labelling. Differing content messages and presentations in the 
three Australian and three French labels were considered. Readability, visual presentations, 
knowledge, attitudes towards and responses to these warnings were compared for the Australian 
sample. Associated information for some of these issues was obtained from a group of French Health 
professionals (n = 98).  In addition a follow-up survey of a sub sample (n = 53) of the hospital 
outpatients was conducted at a later date to determine their responses to the Australian medication 
labelling that had been on the medications reported in use at the time of the recruitment hospital visit. 
It is to be noted that these three samples represent highly informed respondents. Persons recruited in 
a hospital pharmacy are in a situation in which conformity to best practice standards of using labels 
and actively counselling consumers is highly likely to occur. 
5.1 MESSAGE CONTENT 
Using recall of the content of the warning label as an indicator of user response to the message 
content the majority of users recalled messages on medications taken within the last seven days. At 
the same time in the context of this well-informed sample the fact that around 10% did not recall these 
messages is of some concern. 
 
The French Health professionals expressed some concerns about the absence of reference to the 
possible increase of impairment due to alcohol use in the French labelling system. 
5.2 READABILITY 
None of the labels was rated as easiest to read by a majority of respondents. Just over a third 
(37.3%) considered the most serious Australian warning label as the easiest to read and a quarter 
(24%) considered the Level 1 French label (yellow pictogram) as the easiest to read. This finding 
probably indicates that no particular label stood out as easy to read. 
5.3 VISUAL PRESENTATIONS 
The Australian respondents indicated that the most important features of a medication warning label 
in terms of visual impact were its size and the related text size. Colour of the label was also very 
important with the colour “red” being rated as of most importance. Of less importance but still 
considered important by half the sample were the pictograms used in the French warning label 
system and the triangle used in the Australian highest severity warning label. The use of orange and 
yellow colours (French system) was not rated as of high importance in terms of visibility. The 
implications of these findings for driving warning labelling are important. They support the current 
system of using additional labelling over and above the advice provided directly on medication 
packaging.  
 
Whilst there was some variation in the responses of the French doctors and pharmacists the key 
characteristics of colour, size and pictographic presentation emerged as the most important warning 
label features. 
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5.4 KNOWLEDGE OF WARNINGS 
The recall of driving warnings was related to the number of labelled medications that the respondent 
was currently using. The more medications with a warning label used the higher the recall of the 
message content. In the context of the survey being conducted in a hospital pharmacy and the 
findings of the other major Australian general community survey of knowledge of warnings, this 
finding suggests that there is a need to raise community awareness of this aspect of driving safety. 
Participants reported generally accurate knowledge concerning the effects of medicines and other 
substances on driving. However, two of the assessment items were associated with incorrect 
responses. These concerned the risk incurred from exceeding the prescribed medication dose, and at 
the time of commencing treatment.  
5.5 ATTITUDES ASSOCIATED WITH THE WARNING LABELS 
Attitudes were primarily measured through estimates of risk. The most significant finding in relation to 
attitudes related to respondents’ estimates of their potential risk of being involved in a car crash when 
driving if they were taking one of the labelled medications.  The majority (51.2%) rated the French 
highest risk label (Level 3, red pictogram) as that carrying most risk and the highest risk Australian 
label was only considered as the highest risk warning by one fifth (22.2%) of the sample. This finding 
was replicated in respondent’s assessments of the likelihood that they could be involved in a car 
crash when driving after taking a medication with these labels. This may partially reflect an habituation 
response to the Australian label but in the context of the previous assessments supports the French 
labelling system (with pictographs) as more effective if the medication is potentially impairing. 
5.6 RESPONSE TO DRIVING WARNINGS 
Participants’ intentions to comply with the advice of the strongest warning labels in both Australia 
(Label 1) and France (Level 3) were explored by asking participants to rate the likelihood of numerous 
behavioural options. Participants were asked “If you were prescribed a medication displaying Label 1, 
what would you be likely to do?” and the differences in intentions related to the Australian and French 
warning labels were tested for significance using McNemar chi square for paired samples. There were 
no differences in regard to driving when the traffic was less heavy or not taking the medication so that 
they could drive. All other differences were significant with the stronger effect being observed for the 
French label.  It is of concern that at the follow up survey of  this well advised sample of people who 
were on high risk medications only just over half (51%) recalled seeing a warning label on their 
medications. Whilst three quarters (78%) of these respondents reported following the warning label 
advice this still leaves a large proportion of people who do not take the labelling into account in 
making their decisions about driving. 
5.7 CONCLUSIONS AND RECOMMENDATIONS 
The results are potentially important for the Australian approach to medication warnings about driving 
impairment. The research contributes both practical and theoretical findings that can be used to 
enhance the effectiveness of warnings and developing countermeasures in this area. Suggestions for 
future research relate to continued investigation of the effects of medication and other substances on 
driving skills, warning label design, and validation of consumer self-assessment of impairment. This 
project has involved persons with the highest level of likelihood of knowledge and awareness of 
medication warning labelling. Even in this context it would appear that a review of the Australian 
messaging system would be useful particularly in the context of increasing evidence relating to 
associated driving risks. The inclusion of the warning regarding potential increased risk associated 
with alcohol use was well supported. Reviewing text size, readability and simplicity of messages 
including the addition of pictograms as well as clarifying the importance of potential risk in a general 
community context is recommended for consideration and further research. 
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